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Abstract 
Missense mutations in the leucine rich repeat kinase 2 (LRRK2) gene are the 
leading genetic cause of autosomal dominant familial Parkinson’s disease. We 
previously reported that two mutations within the ROC domain, namely 
R1441C and A1442P, exhibit increased protein degradation leading to lowered 
steady state LRRK2 protein levels in HEK293 cells. More recently, the com-
mon WD40 domain LRRK2 haplotype, Met2397, which is a risk factor for 
Crohn’s disease, has been shown to lower steady state protein levels in 
HEK293 cells. In view of recent evidence implicating LRRK2 and inflame- 
mation in PD, we investigated the effects of Met2397 on LRRK2 expression, 
and compared them to the Thr2397 variant and other LRRK2 mutants. In this 
study, we transfected HEK293 cells with plasmid constructs encoding the dif-
ferent LRRK2 variants, and analyzed the resulting protein levels by Western 
blot and flow cytometry. Here we found that both the Met2397 and Thr2397 
haplotypes yield similar levels of LRRK2 protein expression and do not appear 
to impact cell viability in HEK293 cells, compared to other LRRK mutants. 
Thus, we have concluded that the Met2397 haplotype is unlikely to play a role 
in LRRK2 mediated or idiopathic PD. 
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1. Introduction 
Parkinson’s disease (PD) is a neurodegenerative condition characterised by Lewy 
Bodies and the loss of dopaminergic neurons within the substantian igrapars 
compacta [1]. While the majority of PD cases are idiopathic, causative gene mu-
tations have been identified in about 5% - 10% of cases [2]. Of these, missense 
mutations within the leucine-rich repeat kinase 2 (LRRK2) gene appear to ac-
count for the majority of familial cases [3]. The leucine-rich repeat kinase 2 pro-
tein is a member of the ROC kinase family and contains several domains in-
cluding a kinase, a GTPase (ROC/Ras of Complex), COR (Carboxyl-terminus of 
ROC) and multiple protein-protein interaction domains [4]. Pathogenic muta-
tions within the LRRK2 ROC domain account for around 10% of all LRRK2 
mutations, and most commonly affect codon 1441, for which three different 
amino acid substitutions (R1441C/G/H) have been identified [4].  
We previously reported that the ROC domain missense mutation A1442P, 
identified in a Western Australian patient, caused reduced LRRK2 steady state 
protein levels, as did the common R1441C mutation [5]. Mutations within the 
ROC domain of LRRK2 reduce GTP hydrolysis and LRRK2 protein autophos-
phorylation, which leads to dysregulated organelle degradation, altered signal-
ling and ultimately immune dysfunction [1] [6] [7]. However, the effects of mu-
tations and polymorphisms in other domains of LRRK2, such as the WD40 do-
main, are less understood. The WD40 appears to function as a scaffold for pro-
tein-protein complexes in the formation of homodimers, for vesicle trafficking, 
signal transduction, cytoskeleton assembly and autophosphorylation [8]. There-
fore, unsurprisingly, several mutations, or deletion, of this domain have been 
found to contribute to Parkinson’s disease [9] [10]. Furthermore, cell death is 
also regulated by the WD40 domain, as neurotoxicity is reduced in mutants 
lacking the WD40 domain [10]. 
Recently, it was reported that a haplotype (Met2397) variant within the WD40 
domain causes reduced protein stability and may increase susceptibility to 
Crohn’s disease, a serious inflammatory bowel disease [11]. As the Met2397 
haplotype occurs in approximately 50% of the population, we hypothesized that 
the Met2397 haplotype may lead to altered LRRK2 stability and may be a genetic 
modifier in PD. To investigate this proposition, we derived LRRK2 variants of 
each haplotype and determined the effects on steady state protein levels in 
HEK293 cells using flow cytometry and Western blot analysis. 
2. Materials and Methods 
2.1. Site-Directed Mutagenesis  
The LRRK2 Met2397 haplotype was derived by site directed mutagenesis as pre-
viously described [5], using a plasmid pCDNA3.1 encoding the GFP-LRRK2- 
FLAG Thr2397 haplotype as the template. The primer pairs were as follows: 
forward  
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5’-GTGCACTTTTTAAGGGAGGTAAT-GGTAAAAGAAAACAAGGAATGA-3’ 
and reverse  
5’-TGATTCCTTGTTTTCTTTTACC-ATTACCTCCTTAAAAAGTGCAC-3’. 
To confirm the site directed mutagenesis, the resultant constructs were fully se-
quenced. The other plasmid constructs used in this study are previously de-
scribed [5]. 
2.2. Cell Culture and Transfection of HEK293 Cells 
Human embryonic kidney 293 (HEK293) cells were cultured in DMEM (Invi-
trogen, Melbourne, Australia) supplemented with penicillin (20 units/ml), 
streptomycin (20 mg/ml), glutamine (4 mM), 5% foetal calf serum (FCS), and 
maintainedat 37˚C (5% CO2). For transfection, HEK293 cells (150,000) were 
seeded (24-well format) 24 hours prior to transfection with approximately 200 
µM of LRRK2 DNA constructs. Cultures were transfected using Lipofectamine 
2000® in OPTI-MEM serum-free media (Invitrogen) according to the manufac-
turers recommendations. DMEM was added to cells 3 hours post-transfection. 
Fluorescent imaging was undertaken as previously described [12]. Briefly, trans-
fected HEK293 were fixed and visualized for GFP fluorescence (Olympus IX70; 
Olympus DP70 digital camera). 
2.3. RNA Extraction and RT-PCR 
Total RNA was harvested using TRIzol (Invitrogen) according to the manufac-
turer’s instructions. One microgram of total RNA was reverse transcribed using 
M-MLV reverse transcriptase (Promega, Madison, WI, USA). Polymerase chain 
reaction was used to amplify expressedLRRK2 transcripts using forward 
(GGTGAACCGATCGAGCTG) and reverse  
(CTCCAGGATTTGGACCAGCG) primers. For internal controls, expressed 
GAPDH forward (AGAAGGCTGGGGCTCATTTG) and reverse  
(AGGGGCCATCCACAT-CTTC) primers were used. The amplification proto-
col followed 55˚C for 30 min, 95˚C for 2 min and 28 cycles of 95˚C for 30 s, 
51˚C for 30 sec and 72˚C for 45 sec. 
2.4. Flow Cytometry 
HEK293 cells were collected 72 hours post-transfection and washed with phos-
phate-buffered saline (PBS). Cell viability was determined by adding 7AAD (7 
amino actinomycin D; 500 nM; BD Biosciences; San Jose, USA), for 15 minutes 
at room temperature. Cell suspensions were processed by using FACSCalibur 
(BD Biosciences) loaded with Cell Quest software (BD Biosciences), and GFP 
expressing cells were analysed with FlowJo software (version 9.1). A minimum 
of 1 × 105 cells were processed per sample and forward scatter (FSC) and side 
scatter (SSC) detectors were used to measure cell size and gate cell populations 
for analysis. The number of GFP expressing cells was calculated as the percent-
age of green fluorescent cells (live and dead) in the total gated cell population.  
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2.5. Western Blot Analysis 
For protein extraction, cultured HEK293 cells were lysed in buffer (50 mM 
Tris-HCl, pH 7.5, 100 mM NaCl, 20 mM EDTA, 0.1% SDS, 0.2% deoxycholic 
acid), containing complete protease inhibitor (Roche, Indianapolis, USA). West-
ern blotting has been described previously by Anderton, Meloni [13]. Briefly, 
membranes were blocked in PBS-Tween 20 (0.1%)-containing ovalbumin (1 
mg/ml) for 1 hour and incubated in LRRK2 (1:5000; Michael J Fox Foundation; 
New York, USA), GFP (1:5000; Clontech, Palo Alto, CA), FLAG (1:25,000; Sig-
ma-Aldrich, St. Louis, USA), or CYPA (1:40,000; Biomol, Plymouth Meeting, 
PA) primary antibodies diluted in PBS-T (0.1%) plus ovalbumin (1 mg/ml). 
Proteins were detected using a HRP-complexed secondary antibody (1:15,000 - 
1:35,000 donkey anti-rabbit/sheep anti-mouse; GE Healthcare, Piscataway, NJ, 
USA), and visualized using ECL Plus (Bio-Rad, Hercules, USA). Quantification 
and band densitometry of Western blots was undertaken using Image J (NIH) 
software.  
2.6. Statistical Analysis 
Data was analysed using the Statistical Package for Social Sciences (SPSS) soft-
ware, version 24 (IBM Corporation). A univariate analysis of variance (ANOVA) 
was conducted to investigate the main effects of LRRK2 variants, with transfec-
tion (GFP+) and cell viability (GFP+/7AAD+) as the dependent variables. For 
both ANOVAs, if main effects were observed, Bonnferoni post-hoc tests were 
used to investigate the simple effects (i.e. between LRRK2 variants). For all data, 
a p value threshold of <0.05 was considered statistically significant.  
3. Results 
3.1. Generation of a Met2397 LRRK2 Plasmid Construct 
A pcDNA3.1 LRRK2 expression plasmid vector (Origene; Rockville, MD, USA) 
fused with the N-terminus green fluorescent protein (GFP) sequence and FLAG 
peptide sequence has previously been described [5]. The pcDNA3.1 Thr2397 
LRRK2 construct was used as a template for site-directed mutagenesis to pro-
duce the Met2397 LRRK2 haplotype. The LRRK2 expression constructs used in 
this study (Figure 1(a)) include the threonine wild type (Thr2397), methionine 
wild type (Met2397), threonine R1441C (R1441C) and threonine A1442P 
(A1442P). 
3.2. Assessment of LRRK2 Expression in HEK293 Cells 
To determine if the Met2397 haplotype affects LRRK2 protein stability, HEK293 
cells were transfected with equivalent concentrations of plasmid DNA encoding 
the four constructs. Fluorescence imaging of transfected HEK293 cells con-
firmed LRRK2 expression at 48 and 72 hours post-transfection (Figure 1(b)). 
The level of GFP expression in transfected cells appeared to be comparable be-
tween the LRRK2 Thr2397 and Met2397 haplotypes. In comparison and  
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(a) 
 
(b) 
Figure 1. Confirmation of LRRK2 expression. (a) Schematic illustrating the LRRK2 
plasmid constructs containing a GFP and FLAG sequences. The methionine and threo-
nine haplotypes are shown at position 2397 in the WD40 domain. The pathogenic muta-
tion, R1441C, and previously identified, A1442P, were also used in this study. Fluores-
cence microscopy of transfected HEK293 cells; (b) Fluorescence microscopy of wild type 
Thr2397, wild type Met2397, R1441C and A1442P LRRK2 transfected HEK293 images at 
72 hours. 
 
consistent with our previous study, GFP levels appeared to be reduced in 
R1441C and A1442P transfected HEK293 cells (Figure 1(b)) [5].  
3.3. Western Blot Analysis of LRRK2 Protein Levels in  
HEK293 Cells  
Western analysis of LRRK2 protein levels at 72 hours post-transfection showed 
comparable protein levels for both the Met2397 and Thr2397 wild type LRRK2 
haplotypes (Figure 2(a)). Notably, following transfection with R1441C and  
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(a)                                       (b) 
Figure 2. Western blot analysis of transfected HEK293 cells.HEK293 cells were probed 
for FLAG 72 hours after transfection with (a) GFP-fused and (b) non-GFP fused wild 
type Thr2397, wild type Met2397, R1441C and A1442P LRRK2 constructs. Data shown 
are representative blots and accompanying densitometry (n = 3). 
 
A1442P mutants, LRRK2 protein levels were significantly less compared to both 
the Thr2397 and Met2397 haplotype (p < 0.05; Figure 2). To ensure GFP fusion 
was not impacting on protein stability, HEK293 cells were transfected with 
non-GFP fused LRRK2 construct variants. Western blot analysis of non-GFP 
fused LRRK2 proteins (Figure 2(b)) revealed a similar amount of expression 
compared to GFP-LRRK2 fused protein, confirming that that the GFP tag did 
not affect LRRK2 stability. 
3.4. Assessment of LRRK2 Protein Levels in HEK293 Cells  
Using Flow Cytometry 
To quantify LRRK2 protein expression, transfected HEK293 cells were subjected 
to flow cytometry at 72 hours post-transfection. To ensure equivalent concentra-
tions of plasmid DNA were transfected into cells, we performed semi-quantita- 
tive RT-PCR (Figure 3(a)). The percentage of GFP positive cells following 
transfection with the LRRK2 haplotypes was 28.4% (Thr2397) and 27.3% 
(Met2397), which confirmed our Western blot data, that protein levels were 
equivalent. In contrast, the percentage of HEK293 cells expressing GFP was sig-
nificantly reduced in cultures transfected with the mutant LRRK2 constructs 
R1441C (22.6%: p < 0.05) and A1442P (16.9%: p < 0.001).The geometric mean of 
fluorescence (GMF) for GFP did not significantly differ between HEK293 cells 
transfected with the Met2397 and Thr2397 LRRK2 haplotypes (Table 1). How-
ever, there was a significant difference between the wild type haplotypes and 
R1441C (p < 0.05) and A1442P (p < 0.001). 
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(a) 
 
(b) 
 
(c) 
Figure 3. Flow cytometry analysis of transfected HEK293 cells. (a) Semi-quantitative 
RT-PCR analysis of transfected LRRK2 pDNA with GAPDH control mRNA levels; (b) 
HEK cells transfected with wild type GFP-fused Thr2397, wild type Met2397, R1441C and 
A1442P LRRK2 constructs; (c) A representative histogram showing relative LRRK2 ex-
pression as a function of GFP fluorescence for all the expression constructs. Data shown 
are the mean ± standard error; *p < 0.05, ***p < 0.001 (n = 4). 
 
Table 1. Average geometric mean fluorescence (GMF) values following LRRK2 construct 
transfection. 
LRRK2 construct GMF (SD±) 
Thr2397 27.94 (2.98) 
Met2397 28.53 (3.94) 
R1441C 24.25 (1.62) 
A1442P 19.59 (2.65) 
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3.5. The Effect of the LRRK2 2397 Haplotype on HEK293  
Cell Viability 
To determine if type LRRK2 2397 haplotype impacts on cell viability, transfected 
HEK293 cells were stained with 7AAD to determine non-viable cell populations. 
Expression of the wild typeLRRK22397 haplotypes resulted in comparable rates 
of non-viable cells (Figure 4). In contrast, expression of both ROC domain mu-
tants increased cell death. The percentage of cell death in HEK293 cultures 
transfected with the A1442P and R1441C constructs were significantly higher 
compared to both wild type haplotypes (p < 0.005). 
4. Discussion 
Previous studies have suggested that changes to the LRRK2 amino acid sequence 
can significantly affect protein function and stability, potentially contributing to 
PD pathogenesis [5] [14]. Recently, our laboratory reported that mutations in 
the LRRK2 ROC domain led to a decrease in protein stability, causing a protea-
some-mediated degradation to occur more rapidly [5]. The WD40 domain of 
LRRK2 appears to be important in protein-protein interaction, cytoskeletal ac-
tivity, and promoting neuronal survival [8]. The common haplotype within the 
WD40 domain, Met2397, has been linked to immune dysfunction in Crohn’s 
disease [15] due to reduced protein stability, as is also seen with other LRRK2 
domain mutations [11]. 
This study investigated the stability of the LRRK2 Met2397 haplotype along 
with two previously described ROC domain missense mutations (R1441C and 
A1442P). Fluorescent microscopy transfected HEK293 cells revealed that levels 
of LRRK2 protein did not vary between wild type Met2397 and Thr2397  
 
 
Figure 4. Determination of non-viable cells in HEK293 cultures transfected with LRRK2 
constructs. Non-viable cells were determined by positive staining with 7AAD. Transfected 
non-viable cells (GFP+/7AAD+) were analysed by flow cytometry, with results shown as 
levels of cell death. Data shown are the mean ± standard error; **p < 0.005 (n = 3). 
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haplotypes. Furthermore, Western blot analysis of FLAG demonstrated compa-
rable protein levels when comparing wild type haplotypes. Surprisingly, these 
results contradict previous findings that showed expression of the wild type 
LRRK2 Met2397 haplotype produced a less stable protein than the Thr2397 
haplotype, when expressed in HEK293 cells [11]. Further, LRRK2 protein levels 
were reduced in the peripheral blood B-cells of patients homozygous for the 
Met2397 haplotype [11]. In order to further investigate the disparity between 
our findings and those of Liu et al. (2011), LRRK2 protein levels were quantified 
using flow cytometry. Similarly, there were no differences in mean geometric 
fluorescence or GFP positive cells 72 hours after transfection with Met2397 or 
Thr2397 LRRK2 constructs. One possible cause for such findings in the present 
study is the difference in expression constructs. However, use of a previously 
validated and sequenced construct [5] supports the current findings, suggesting 
a presently unknown mechanism for the contradictory results. 
This study also investigated the effect of ROC and WD40 mutations on 
LRRK2 protein stability, and subsequent cell viability. As previously stated, the 
WD40 domain functions in vesicle trafficking, signal transduction, cytoskeleton 
assembly and autophosphorylation [8]. Most importantly, the WD40 domain 
has been linked to cell viability, as neurotoxicity is reduced in mutants lacking 
the WD40 domain [10]. The missense mutation, G2385R, which is located in the 
WD40 domain close to the 2397 codon, reportedly reduces the cell’s ability to 
handle oxidative stress, impacting on cell survival [16]. Following flow cytome-
try analysis, 7AAD staining of LRRK2 expressing HEK293 cells was used to 
quantify levels of cell death. Our results showed no differences between the wild 
type Met2397/Thr2397 haplotypes, suggesting the Met2397 haplotype is not di-
rectly implicated in the neuronal loss seen in Parkinson’s disease. 
Previous studies into the LRRK2 protein have identified the ROC domain as 
being important in the maintenance of protein stability [17]. In this study, 
HEK293 cells expressing R1441C and A1442P ROC mutants showed reduced 
viability, in comparison to wild type Met2397/Thr2397 haplotypes. A decrease in 
cell viability has been linked to the R1441C mutation and other LRRK2 missense 
mutations including the Y1699C, G2019S and I2020T mutations, in both im-
mortalised and primary cells [7] [14] [18] [19]. 
Interestingly, the LRRK2 protein has also been linked to the regulation of 
immune signalling, such as those mediated by the Toll-like Receptor (TLR) in 
microglia and B cells, which cause the release of TNFα and interleukin-6 in re-
sponse to pathogens [20]. The LRRK2 protein has been reported to down-re- 
gulate the NFAT signalling pathway, and LRRK2 knockout in vivo results in the 
over-production of inflammatory cytokines [11]. Indeed, the R1441G ROC do-
main missense mutation is also reported to increase inflammatory cytokine re-
lease [21]. Therefore, the reduction in cellular LRRK2 protein levels could be di-
rectly linked to the over-production of inflammatory cytokines detected in the 
brains and spinal fluid of PD patients [22] [23] [24]. 
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In this study, we have confirmed that the ROC domain missense mutations, 
R1441C and A1442P, decrease LRRK2 protein stability. Furthermore, for the 
first time this study demonstrates that the A1442P missense mutation causes de-
creased cell viability in HEK293 cells. However, the results from this study indi-
cate that the Met2397 haplotype does not impact LRRK2 protein stability or cell 
viability, conflicting with previous reports by Liu et al. (2011). While the present 
study was limited by ectopic expression of LRRK2, both GFP and non-GFP 
fused LRRK2 constructs revealed similar findings on protein stability. In conclu-
sion, we have investigated the impact of the Met2397/Thr2397 haplotype and 
provided further evidence for the involvement of the ROC domain in LRRK2 
protein survival. These findings suggest the LRRK2 Met2397 haplotype variation 
is unlikely to play a significant role in the pathogenesis of LRRK2-mediated PD.  
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